Randomized trial · people
Retatrutide: non-HDL cholesterol down up to 26.9% in phase 2 trials
Checked against the paper Randomized trialPublished by PepVault
The takeaway
In these phase 2 trials, retatrutide lowered several blood fat markers linked to heart risk with and without diabetes, and inflammation markers fell only in the group without diabetes.
- Kind
- Randomized trial
- Studied in
- People
- Published
- 2026
- Journal
- Diabetes Obes Metab
What they tested
The team wanted to see how retatrutide changes blood fats and inflammation markers tied to heart disease risk in adults with obesity or overweight, with or without type 2 diabetes.
How the study was done
A post hoc look at two randomized, double-blind, placebo-controlled phase 2 trials. Study 1 gave adults with obesity or overweight and type 2 diabetes weekly retatrutide (0.5, 4, 8 or 12 mg), dulaglutide 1.5 mg or placebo (a dummy shot) for 36 weeks, and Study 2 gave adults with obesity but no diabetes weekly retatrutide (1, 4, 8 or 12 mg) or placebo for 48 weeks.

What they found
Average body mass index was 35.4 kg/m2 in Study 1 and 37.4 kg/m2 in Study 2. Compared with placebo, retatrutide lowered non-HDL cholesterol by up to 21.0% in Study 1 and up to 26.9% in Study 2, and apolipoprotein B (apoB, a count of artery-clogging fat particles) fell by 21.4% and 24.2%. Small LDL particles dropped by 32.6% and 32.3%, and large triglyceride-rich lipoprotein particles by 84.4% and 76.6%. In Study 2 only, high-sensitivity C-reactive protein fell by 54.8% and interleukin-6 by 29.6%, while neither marker changed significantly in Study 1.
What it doesn’t show
This was a post hoc analysis of phase 2 trials, so it was not the main question the trials were built to answer. It measured blood markers, not heart attacks, strokes or other heart events.
The paper
Ruotolo et al. Retatrutide-Associated Improvements in Cardiovascular Risk Biomarkers in Adults With Obesity With or Without Type 2 Diabetes. Diabetes Obes Metab. 2026.
The compound
More studies on Retatrutide
- Retatrutide: top odds of 15% or more weight loss across 19 trialsMeta-analysis · people · 2025
- Retatrutide: up to 25.0% weight loss at 80 weeks in TRIUMPH-1Randomized trial · people · 2026
- Retatrutide: 26.1% fat mass loss at 36 weeks in type 2 diabetesRandomized trial · people · 2025
- Retatrutide: up to 82.4% less liver fat at 24 weeks in MASLD trialRandomized trial · people · 2024
- Retatrutide: 24.2% weight loss at 48 weeks in the 12 mg armRandomized trial · people · 2023
- Retatrutide: up to 8.96 kg placebo-adjusted weight loss in 12 weeksRandomized trial · people · 2022
- Every study on Retatrutide
Researched and drafted with AI, then checked claim by claim against the primary sources linked below by a separate review pass. Published by PepVault. Last reviewed . Spot an error? feedback@pepvault.app. How we research. This page reports one study; it is not medical advice.